

Personalised Cancer Medicine Flashcards 2025

Lung Cancer



Standard

PDL-1 + NGS

Alternative: PDL-1 + secuential gene testing

KRAS*
EGFR*
ALK*
ROS1*
MET*
RET*
NTRK*



Recommended

HER2*
BRAF*
NRG1*

Currently not recommended

TROP-2
KEAP1, STK11, MSI, or
TMB (with NGS)

* If a single test is performed due to the non-availability of NGS or limited material, a sequence of testing (related by the probability of the molecular alterations) is suggested

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System

The **Recommended** category is based on current recommendations by EMEA and FDA

1. Isla D, Lozano MD, Paz-Ares L, et al. Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol. 2023 Apr-Jun;56(2):97-112. Spanish. doi: 10.1016/j.patol.2023.02.002.
2. Colomer R, Mondejar R, Romero-Laorden N et al. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.
3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014..
4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

